TY - JOUR
T1 - Drug repurposing in oncology, an attractive opportunity for novel combinatorial regimens
AU - Falvo, Paolo
AU - Orecchioni, Stefania
AU - Roma, Stefania
AU - Raveane, Alessandro
AU - Bertolini, Francesco
N1 - Funding Information:
This work has been supported by Associazione Ital-iana per la Ricerca sul Cancro (AIRC), “Grant Number IG20109” awarded to Dr.Francesco Bertolini, and by the Italian Ministry of Health
Funding Information:
The authors acknowledge the financial support from AIRC and the Italian Ministry of Health.
Publisher Copyright:
© 2021 Bentham Science Publishers.
PY - 2021
Y1 - 2021
N2 - The costs of developing, validating and buying new drugs are dramatically increasing. On the other hand, sobering economies have difficulties in sustaining their healthcare systems, particularly in countries with an elderly population requiring increasing welfare. This conundrum requires immediate action, and a possible option is to study the large, already present arsenal of drugs approved and to use them for innovative therapies. This possibility is particularly interesting in oncology, where the complexity of the cancer genome dictates in most patients a multistep therapeutic approach. In this review, we discuss a) Computational approaches; b) preclinical models; c) currently ongoing or already published clinical trials in the drug repurposing field in oncology; and d) drug repurposing to overcome resistance to previous therapies.
AB - The costs of developing, validating and buying new drugs are dramatically increasing. On the other hand, sobering economies have difficulties in sustaining their healthcare systems, particularly in countries with an elderly population requiring increasing welfare. This conundrum requires immediate action, and a possible option is to study the large, already present arsenal of drugs approved and to use them for innovative therapies. This possibility is particularly interesting in oncology, where the complexity of the cancer genome dictates in most patients a multistep therapeutic approach. In this review, we discuss a) Computational approaches; b) preclinical models; c) currently ongoing or already published clinical trials in the drug repurposing field in oncology; and d) drug repurposing to overcome resistance to previous therapies.
KW - Computational approaches
KW - Drug
KW - In silico
KW - Oncology
KW - Preclinical models
KW - Repurposing
KW - Therapies
UR - http://www.scopus.com/inward/record.url?scp=85104960549&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104960549&partnerID=8YFLogxK
U2 - 10.2174/0929867327999200817104912
DO - 10.2174/0929867327999200817104912
M3 - Review article
C2 - 33109033
AN - SCOPUS:85104960549
VL - 28
SP - 2114
EP - 2136
JO - Current Medicinal Chemistry
JF - Current Medicinal Chemistry
SN - 0929-8673
IS - 11
ER -